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This study was performed to analyze the efficacy of the
prophylactic use of octreotide (Novartis, Stein, Switzerland)
for pancreatic fistula following a pancreaticoduodenectomy.
The medical records of 190 patients who underwent a pancrea-
ticoduodenectomy at the Samsung Medical Center in Seoul,
Korea between January 2000 and December 2002 were re-
viewed. Patients were divided into either the octreotide (n =
81) or control group (n = 109). The octreotide group received
subcutaneous injections of 100 g of octreotide every 12 hours μ
for more than five days after surgery. The control group was
not treated with octreotide. The criterion of pancreatic fistula
was the drainage of the amylase rich fluid, over 500 U/mL in
the three days after surgery. The morbidity and mortality rates
were 32.1% and 1.2% in the octreotide group and 31.2% and
0% in the control group, respectively. Pancreatic fistula was
the second most common complication (8.4%). In the univari-
ate analysis, octreotide was ineffective in reducing pancreatic
fistula (p = 0.26). However, in the multivariate regression an-
alysis, combined gastrectomy (p = 0.018), cellular origin of the
disease (p = 0.049), and use of octreotide (p = 0.044) were the
risk factors that increased the frequency of pancreatic fistula.
Therefore, the routine use of octreotide after a pancreaticoduo-
denectomy should be avoided until a worldwide consensus is
established.
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INTRODUCTION
Pancreatic fistula after a pancreaticoduodenec-
tomy is a common, but dangerous complication.
1-3
The major causes of mortality after a pancreatico-
duodenectomy are intra-abdominal sepsis or
hemorrhage, which frequently precedes pancreatic
fistula.
4,5 These complications also prolong the
hospital stay after surgery. Thus, pancreatic sur-
geons have been interested in the prevention of
pancreaticoduodenectomy-related pancreatic fis-
tula. Several techniques and modifications for the
management of the residual pancreas have been
developed.
6-9 However, a standard technique for
the reduction of pancreatic fistula has not yet been
determined.
The outcome of clinical trials evaluating the ef-
ficacy of various drugs for the prevention of fis-
tula formation remains controversial. Although
prospective randomized studies conducted in
Europe showed that perioperative treatment using
octreotide as a prophylaxis was associated with a
lower incidence of pancreatic fistula,
10-13 the pro-
spective randomized placebo-controlled studies
performed in North America revealed that the
prophylactic use of octreotide should be elimi-
nated.
14,15 Even meta-analysis studies showed con-
tradictory results in the effectiveness of pro-
phylactic octreotide.
16-18
In our hospital, the synthetic somatostatin an-
alogue octreotide
19 has been used since 1995 for
the prevention of pancreatic fistula associated
with a pancreaticoduodenectomy. Recently, the
use of octreotide has increased due to the pro-
pensity of individual surgeons. Here, we evaluate
the efficacy of octreotide, administered after a
pancreaticoduodenectomy, in preventing pancre-
atic fistula. In this study, pancreatic fistula refers
to the drainage of more than 500U/mL of amylase-
rich fluids during the three days after surgery or
overt clinical findings, regardless of the amount of
turbid drainage fluid, leukocytosis, erosion of the
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MATERIALS AND METHODS
Between January 2000 and December 2002, 237
patients underwent a pancreaticoduodenectomy
in the Department of Surgery at Samsung Medical
Center in Seoul, Korea. The following patients
were excluded from the study: 16 patients who
had a total pancreatectomy and 31 patients treated
with octreotide for less than five days or without
immediate treatment after the operation. The
remaining 190 patients were examined. The con-
trol group included 109 patients who had never
received octreotide, while the octreotide group
consisted of 81 patients treated with octreotide,
via a subcutaneous injection of 100 g every 12 μ
hours for more than five days (9.38 days ± 8.88)
immediately following the surgery. Whether
octreotide was administered or not was based on
the individual surgeons' propensity for octreotide,
which was believed to have changed over time.
Therefore, the number of patients in the octreotide
group increased with time, with 71.6% of the
group seen in the last half of the study.
Pancreaticoduodenectomies were performed
according to the classic Whipple procedure or via
a pylorus-preserving method. All pancreaticoje-
junostomies were carried out with either the end-
to-end or end-to-side telescoping (invagination/
double layer) method. A short silicon stent was
routinely intubated into the remaining pancreatic
duct, depending on the duct's diameter. The tip
of the tube was placed 1.0 - 1.5 cm into the jeju-
num. Also, two closed-suction drains were in-
serted through the separated site and placed in
the vicinity of the pancreaticojejunostomy in order
to prevent direct contact with the anastomotic site.
Statistical analysis was made using SPSS 11.0
for Windows. To compare the incidence of pan-
creatic fistula in the two groups, Chi-square statis-
tics, Fisher's exact test, and the Student's t-test
were used. A p-value of less than 0.05 was con-
sidered significant. Multivariate comparison was
made using a logistic regression of the variables
that were originally used in the univariate an-
alysis.
RESULTS
Among the 190 patients who underwent a
pancreaticoduodenectomy, 60 patients (31.6%) had
one or more complications (32.1% in the octreo-
tide group and 31.2% in the control group). The
most common complication was hemorrhage
(8.9% overall, 7.4% in the octreotide group, and
10.1% in the control group), followed by pan-
creatic fistula (8.4% overall, 9.9% in the octreotide
Table 1. Complications after Pancreaticoduodenectomy
Variable
No. of patients (%)
Octreotide group Control group Total
Hemorrhage* 6 (7.4) 11 (10.1) 17 (8.9)
Pancreatic fistula 8 (9.9) 8 (7.3) 16 (8.4)
Delayed gastric emptying 5 (6.2) 10 (9.2) 15 (7.9)
Wound complication 6 (7.4) 6 (5.5) 12 (6.3)
Biliary fistula 4 (4.9) 6 (5.5) 10 (5.2)
Intra-abdominal abscess 3 (3.7) 5 (4.6) 8 (4.2)
Pulmonary complication 1 (1.2) 3 (2.8) 4 (2.1)
Chyle leakage 2 (2.5) 0 (0) 2 (1.0)
Newly developed DM 0 (0) 2 (1.8) 2 (1.0)
Total 26 (32.1) 34 (31.2) 60 (31.6)
DM, diabetes mellitus.
*One patient died of a hemorrhage (0.5%).
Patients had one or more complications.Hyoun Jong Moon, et al.
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group, and 7.8% in the control group), and de-
layed gastric emptying (7.9% overall, 6.2% in the
octreotide group, and 9.2% in the control group).
One patient from the octreotide group died from
hemorrhage (0.5%) (Table 1).
Comparing the octreotide and control groups,
the differences in gender, mean age, preoperative
biliary drainage, histological diagnosis, median
operation time, origin of disease, incidence of
complication, and incidence of pancreatic fistula
were not statistically significant. On the other
hand, the differences in the combined gastrectomy
(p<0.001), intra-operative transfusion (p = 0.009),
and duration of post-operative hospital stay (p =
0.015) were significant (Table 2). The combined
gastrectomy and intra-operative transfusion were
considered to be effect modifiers, rather than com-
pounders. In the multivariate comparison for the
association of pancreatic fistula with perioperative
factors, the use of prophylactic octreotide (p =
0.044), cellular origin of the disease (p = 0.049),
and combined gastrectomy (p = 0.018) were se-
lected as the independent variables (Table 3).
DISCUSSION
Our data showed that the use of octreotide to
Table 2. Demographic and Clinicopathologic Characteristic of Patients
Variable Octreotide group (n = 81) Control group (n = 109) Total (n = 190) p value
Gender
Male
Female
49 (60.5)
32 (39.5)
64 (58.7)
45 (41.3)
113 (59.5)
77 (40.5)
0.805
Mean age (yrs) 58.8 57.7 58.2 0.461
Preoperative biliary drainage
Yes
No
41 (50.6)
40 (49.4)
67 (61.6)
42 (38.5)
108 (56.8)
82 (43.2)
0.135
Histological diagnosis
Malignant
Pancreatic adenocarcinoma
Periampullary adenocarcinoma
Neuroendocrine carcinoma
Other malignant tumor
Benign
72 (88.9)
19 (23.5)
50 (61.7)
3 (3.7)
0 (0)
9 (11.1)
97 (89.0)
22 (20.2)
71 (65.1)
2 (1.8)
2 (1.8)
12 (11.0)
169 (88.9)
41 (21.6)
121 (63.7)
5 (2.6)
2 (1.1)
21 (11.1)
0.982
Combined gastrectomy
Yes
No
22 (27.2)
59 (72.8)
87 (79.8)
22 (20.2)
109 (57.4)
81 (42.6)
<0.000
Median operating time (hours) 5.56 5.68 5.63 0.386
Intraoperative transfusion
Yes
No
20 (24.7)
61 (75.3)
47 (43.1)
62 (56.9)
67 (35.3)
123 (64.7)
0.009
Cellular origin of disease
Pancreas other organs
25 (30.9)
56 (69.1)
24 (25.0)
85 (75.0)
49 (25.8)
141 (74.2)
0.168
Pancreatic fistula
Yes
No
8 (9.9)
73 (90.1)
8 (7.3)
101 (92.7)
16 (8.4)
174 (91.6)
0.533
Patients having complication
Yes
No
26 (32.1)
55 (67.9)
34 (31.2)
75 (68.8)
60 (31.6)
130 (68.4)
0.894
Postoperative hospital stay (days) 20.4 26.0 23.7 0.015The Efficacy of the Prophylactic Use of Octreotide after a Pancreaticoduodenectomy
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prevent pancreatic fistula after a pancreaticoduo-
denectomy is ineffective. Since this study was not
a prospective randomized trial, we failed to deter-
mine a clear indication for the administration of
octreotide, other than simply a change in the
surgeons' propensity. However, we recommend
discontinuing routine use of octreotide a pancrea-
ticoduodenectomy, based on our results. Although
several prospective randomized studies
6,10,12-15 and
meta-analyses
16-18,20 have investigated the effect of
octreotide after a pancreatectomy, no clear con-
clusion can be made since the results of these
studies were contradictory. This may be attributed
to the variations in the definition of pancreatic
fistula, patient characteristics, dosages of octreo-
tide, perioperative treatment modalities, and sur-
gical procedures. Thus, an international consensus
on the definition of pancreatic fistula after a
pancreaticoduodenectomy should be reached
prior to the routine prophylactic use of octreotide
for pancreatic fistula.
Pancreatic fistula is defined according to the
concentration of amylase in the drainage fluid,
volume of drainage, and clinical manifestation. In
1992, Buchler et al.
10 defined it as a concentration
of amylase in the drainage fluid three times more
than the serum concentration, and a drainage vol-
ume of more than 10 mL during a 24 hour period.
Patients were injected subcutaneously with 100 g μ
of octreotide every eight hours for seven days. In
1994, Pederzoli et al.
12 defined pancreatic fistula as
the presence of drainage fluid exceeding 10 ml per
24 hours for at least four days, starting from the
fourth day after the operation, and an amylase
content of at least three times more than the maxi-
mum normal value. In 1997, Lowy et al.
14 defined
it as the clinical pancreatic anastomotic leak (2.5
times more than the upper limit of the normal
serum amylase) in association with a fever (over
38 ), leukocytosis (a white blood cell count over
10,000/L), sepsis (homodynamic instability re-
quiring treatment in the intensive care unit), or a
need of percutaneous drainage of the amylase-rich
fluid collection. They also defined it as a bioche-
mical pancreatic anastomotic leak with an ele-
vated level of amylase (more than 2.5 times higher
than the upper limit of normal serum amylase) in
the drainage fluid or three days after surgery,
even if it was asymptomatic and resolved sponta-
neously. Such patients were treated subcutane-
ously with 150 g of octreotide every eight hours μ
for five days. In 2000, Yeo et al.
15 defined pancre-
atic fistula as a drainage of greater than 50 mL of
amylase-rich fluid (three-fold more than the nor-
mal upper limit in the serum) per day by surgi-
cally placed drains or ten days after surgery, or
pancreatic anastomotic disruption demonstrated
by a radiograph. Such patients were treated sub-
cutaneously with 250 g of octreotide every eight μ
hours for seven days, until the fistula resolved.
We defined pancreatic fistula as more than 500
U/mL of amylase-rich fluid from the surgical
drain three days after surgery. Such patients were
treated with 100 g of octreotide subcutaneously μ
every 12 hours.
Without proper adjustment to the various defi-
nitions of pancreatic fistula, as well as variation in
the dosage of octreotide among the reported
studies, it is difficult to reach a conclusion on the
use of octreotide treatment based on the practice
of evidence-based-medicine. Until there is a con-
sensus on the definition of pancreatic fistula and
the proper dosage of octreotide is established by
new prospective randomized studies, the results
obtained by an individual institution should be
considered only as a sample applicable to their
own conditions.
In our study, the incidence of pancreatic fistula
was influenced independently by the cellular
origin of the disease and combined gastrectomy
(Table 3). In most studies, the personal technical
skill of the surgeons and the hardness of the re-
Table 3. Significant Factors Associated with Pancreatic Fistula Analyzed by Multivariate Analysis
Variable Relative risk 95% CI p value
Octreotide 3.64 1.036 - 12.784 0.044
Cell of origin 8.32 1.010 - 68.619 0.049
Combined gastrectomy 5.41 1.338 - 21.866 0.018
CI, confidence interval.Hyoun Jong Moon, et al.
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sidual pancreas have been reported to be impor-
tant factors in the occurrence of complications
after a pancreaticoduodenectomy.
1-2,21-27 In some
studies, patients who underwent a pancreatico-
duodenectomy were classified into high-risk and
low-risk groups,
10,12,14 which were dependent on
the hardness of the remaining pancreas and the
amount of pancreatic secretion. In our study, the
cellular origin of the disease was considered to be
a main factor in determining the feasibility of a
pancreaticojejunostomy. We observed that the in-
cidence of pancreatic fistula in the pylorus pre-
serving pancreaticoduodenectomy was lower than
in the conventional pancreaticoduodenectomy
(Table 3). Even though the mechanism is unclear,
this could be attributed to the unknown function
of the remaining duodenum, preserved pylorus,
or gastric antrum in contributing to healing after
a pancreaticojejunostomy. The remaining stomach
and the lesser omentum may alternately protect
the anterior pancreaticojejunostomy site.
In our study, the incidence of pancreatic fistula
was not different between the control and octreo-
tide groups. However, in the patients treated with
octreotide, the pylorus preserving pancreatico-
duodenectomy was the most favorable prognosis
factor. This suggests that the prophylactic use of
octreotide was not a favorable prognosis factor.
We recommend the selective prophylactic use of
octreotide in high-risk patients with a soft pan-
creas and a small pancreatic duct (under 3 mm).
In addition, the indication of octreotide for pro-
phylaxis of a pancreatic fistula should be adjusted
by individual institutions based on their mortality
and morbidity rates.
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